.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,945,416

« Back to Dashboard
Patent 5,945,416 protects SYMBYAX and is included in one NDA. There have been two Paragraph IV challenges on Symbyax.

This patent has twenty-one patent family members in fifteen countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 5,945,416

Title: Method for treating pain
Abstract:The present invention provides a method for treating pain using a composition comprising olanzapine and Drug Useful in the Treatment of Pain.
Inventor(s): Shannon; Harlan E. (Carmel, IN), Womer; Daniel E. (Thornton, CO)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:08/823,461
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 2nd percentile
Forward Citations: 5th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-002Dec 24, 2003RXNo5,945,416► subscribeYYY
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-004Dec 24, 2003RXNo5,945,416► subscribeYYY
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-003Dec 24, 2003RXYes5,945,416► subscribeYYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: 5,945,416

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
5,945,416 August 31, 2011

International Patent Family for Patent: 5,945,416

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2543097► subscribe
Australia725556► subscribe
Brazil9708254► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc